Myasthenia Gravis
Welcome,         Profile    Billing    Logout  
 64 Companies   21 Products   21 Products   23 Mechanisms of Action   207 Trials   10745 News 


«12...3637383940414243444546...136137»
  • ||||||||||  methimazole / Generic mfg.
    Thymic Hyperplasia inGraves' Disease: An Under-recognized Association (ENDOExpo) -  May 11, 2023 - Abstract #ENDO2023ENDO_2161;    
    Initiation of methimazole normalized thyroid function...1 Biopsy and thymectomy should be deferred when thyrotoxic due to risk of precipitating thyroid storm4 and be reconsidered if thymus fails to regress on repeat imaging.Additional guidance for observation is needed as the differential diagnosis for mediastinal mass includes diseases warranting more urgent diagnosis and intervention. Identification of high-risk patient characteristics or imaging findings may be of clinical utility in this circumstance.
  • ||||||||||  Bilateral Sporadic Carotid Paraganglioma as a Rare Cause of Syncope (ENDOExpo) -  May 11, 2023 - Abstract #ENDO2023ENDO_804;    
    Her conservative management plan included a cardiology work-up for symptom-directed therapy with a pacemaker placement.ConclusionRecurrent syncope is an uncommon presentation of carotid body tumors requiring workup to rule out functionality, genetic mutations, and metastases. Management involves a multi-disciplinary approach and individual risk-benefit assessment of treatment options.
  • ||||||||||  Worsening Shortness of Breath After a Mild Case of Covid-19 (ENDOExpo) -  May 11, 2023 - Abstract #ENDO2023ENDO_502;    
    This patient will require repeated imaging and follow up. The long-term consequences of this finding are unknown and this patient has a history of night sweats which preceded the COVID course.
  • ||||||||||  methimazole / Generic mfg., propranolol / Generic mfg.
    A Study of 21 Cases of Graves Disease in Childhood Presenting at Our Hospital for the First Time (ENDOExpo) -  May 11, 2023 - Abstract #ENDO2023ENDO_120;    
    Fourteen patients received propranolol...Symptoms related to poor academic performance were also considered important. Anti-thyroglobulin antibodies and anti-TPO antibodies were also detected, suggesting that we should be careful about the possibility of the disease progressing to Hashimoto's disease.
  • ||||||||||  Review, Journal:  Cogan's Lid Twitch for Myasthenia Gravis: A Systematic Review. (Pubmed Central) -  May 11, 2023   
    Cogan's lid twitch is a physical examination finding with moderate diagnostic performance in the diagnosis of myasthenia gravis with ocular involvement. Future studies may seek to evaluate the performance of Cogan's lid twitch in conjunction with other signs of myasthenia gravis with ocular involvements, such as fatigable ptosis or a positive icepack test.
  • ||||||||||  Journal:  Myasthenia Gravis: Novel Findings and Perspectives on Traditional to Regenerative Therapeutic Interventions. (Pubmed Central) -  May 10, 2023   
    also, to increase survival and QoL, further recent developments revealed that antibody, gene, and regenerative therapies (such as stem cells and exosomes) are currently being investigated as a safer and more efficacious alternative. Considering these above-mentioned points, we have comprehensively reviewed the recent advances in pathological etiologies of MG including COVID-19, and its therapeutic management.
  • ||||||||||  Zilbrysq (zilucoplan) / UCB
    Trial completion date, Trial primary completion date:  RAISE-XT: Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis (clinicaltrials.gov) -  May 10, 2023   
    P3,  N=200, Active, not recruiting, 
    Considering these above-mentioned points, we have comprehensively reviewed the recent advances in pathological etiologies of MG including COVID-19, and its therapeutic management. Trial completion date: Apr 2024 --> Jun 2026 | Trial primary completion date: Apr 2024 --> Jun 2026
  • ||||||||||  amoxicillin / Generic mfg.
    CASE REPORT: POST COVID BLEPHAROPTOSIS IN A CHILD OF 2 YEARS OLD () -  May 6, 2023 - Abstract #ESPID2023ESPID_1856;    
    Fifteen days before admission, he was treated with amoxicilline for an unidentified upper respiratory infection...Learning Points/ We report a rare to our knowledge case of a very young boy who presented third nerve palsy- after a SARS-Cov2 infection with great outcome after receiving immmunoglobulines.. Whether the virus revealed or aggravayed an underlying condition or whether the SARS-Cov-2-induced immune system dysregulation is responsable are questions that demand more standardized studies, especially in children where the symptoms and pathophysiological mechanisms differ from those in adults and are not related to the severity of the SAR-Cov2 infection.
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Journal:  Clinical course and outcome of Covid-19 in patients with myasthenia gravis. (Pubmed Central) -  May 5, 2023   
    Three of the exitus patients were receiving rituximab therapy...The vast majority of the MG patients made a good recovery from Covid-19. The risk of severe COVID-19 is high in patients with high MG-ADL severity scores and a history of myasthenic crisis.
  • ||||||||||  NEUROLOGICAL DISEASES TREATED WITH PLASMAPHERESIS PERFORMED BY NEPHROLOGISTS (Focussed Oral Room 10) -  May 4, 2023 - Abstract #ERAEDTA2023ERA_EDTA_1599;    
    We, as nephrologists must be aware of this and promote the management of this technique by publishing the joint experience in order to broaden the level of evidence in clinical practice. The importance of coordination in early referral by other different medical specialties may obtain better results.
  • ||||||||||  Journal:  Autoimmune alopecia areata due to thymoma without myasthenia gravis: a case report. (Pubmed Central) -  May 3, 2023   
    In our center, principal indications for TPE were myasthenia gravis, NMDA encephalitis and Guillain-Barr Although alopecia areata is a rare complication in thymoma cases without myasthenia gravis, thoracic surgeons need to keep this condition in mind because alopecia reduces the patient's quality of life.
  • ||||||||||  Review, Journal:  TOR1AIP1-Associated Nuclear Envelopathies. (Pubmed Central) -  May 2, 2023   
    We then review the mutations in the TOR1AIP1 gene and the clinical and pathological characteristics of subjects with these mutations. Lastly, we discuss challenges to be addressed in the future.
  • ||||||||||  Review, Journal:  Two case reports and a literature review of typical GBS and rare GBS variants associated with COVID-19. (Pubmed Central) -  May 1, 2023   
    There have been numerous reports of adult patients with the coexistence of GBS disease and active COVID-19 illness, but this number is lacking for children. In this study, we present a literature review of the etiological correlation between SARS-CoV-2 and GBS and describe the cases of two pediatric patients with acute monophasic Guillain-Barr
  • ||||||||||  Journal:  Comparing the Impact of COVID-19 on Vaccinated and Unvaccinated Patients Affected by Myasthenia Gravis. (Pubmed Central) -  Apr 28, 2023   
    Similarly, older age at MG onset and at the time of infection correlated with a more severe COVID-19 course in non-vaccinated patients (p = 0.03 and p = 0.04), but not in the group of vaccinated patients. In summary, our data support a protective role of vaccination in myasthenic patients, even if anti-CD20 therapy might be associated with a poor immune response to vaccines.
  • ||||||||||  Comirnaty (tozinameran) / Pfizer, Fosun Pharma, BioNTech
    Effect of SARS-CoV-2 mRNA vaccine booster in serologically negative patients with thymic epithelial tumors. () -  Apr 26, 2023 - Abstract #ASCO2023ASCO_6392;    
    It remains to be investigated why half of the patients are still not achieving seroconversion after the booster and whether this is determined by the presence of active disease or by alterations in humoral and/or cell-mediated immune response. These data may have important clinical implications because they could help to better identify fragile patients who could benefit from improved vaccine protocols or from alternative prophylaxis strategies, such as the use of monoclonal antibodies.
  • ||||||||||  Imjudo (tremelimumab) / AstraZeneca, Pfizer, Avastin (bevacizumab) / Roche, Imfinzi (durvalumab) / AstraZeneca
    A phase II study of tremelimumab, durvalumab, and bevacizumab in advanced biliary tract cancers. () -  Apr 26, 2023 - Abstract #ASCO2023ASCO_5099;    
    P2
    In contrast, historical data showed limited benefit with D+T alone in BTC. We observed that modifying dosing schedule may impact outcomes by reducing efficacy when the three drugs are not given together.
  • ||||||||||  Gamunex (intravenous normal human immunoglobulin 10%) / Bayer, Grifols, Kedrion
    Journal:  Reply to: Intravenous immunoglobulin (Gamunex (Pubmed Central) -  Apr 26, 2023   
    With similar patterns among low grade events, an underlying mechanism of molecular mimicry seems more likely. No abstract available
  • ||||||||||  Review, Journal:  Microbiota dysbiosis and myasthenia gravis: Do all roads lead to Rome? (Pubmed Central) -  Apr 25, 2023   
    This review summarizes the role of gut microbiota and their metabolites (postbiotics) in the progression of MG. Also, various bacteriotherapeutic approaches involving gut microbiota are discussed for the prevention of MG progression.
  • ||||||||||  Biomarker, Review, Journal:  Circulating Calprotectin (cCLP) in autoimmune diseases. (Pubmed Central) -  Apr 25, 2023   
    At 3 Our literature review supports a relevant role of cCLP as potential prognostic biomarker mirroring local or systemic inflammation, especially in chronic inflammatory rheumatic diseases.
  • ||||||||||  Journal:  Impact of Early Treatment with Intravenous High-Dose Methylprednisolone for Ocular Myasthenia Gravis. (Pubmed Central) -  Apr 25, 2023   
    Despite having greater clinical severity before immunotherapy and lower oral prednisolone doses throughout the course, the early IVMP group (n?=?55) showed a higher rate of achievement of MM (P?=?0.0040, log-rank test; hazard ratio 1.58, 95% confidence interval [CI] 1.13-2.20, P?<?0.0001) and MM5mg (P?=?0.0005, log-rank test; hazard ratio 1.78, 95% CI 1.27-2.51, P?<?0.0001) compared with the non-early IVMP group (n?=?149). In conclusion, an early intervention with IVMP is likely to increase the probability of achieving a better long-term outcome and reducing the total dose of corticosteroids in ocular MG.
  • ||||||||||  Biomarker, Trial completion date, Trial primary completion date:  Predictors and Prognostic Factors of Myasthenia Gravis Outcome (clinicaltrials.gov) -  Apr 25, 2023   
    P=N/A,  N=30, Recruiting, 
    In conclusion, an early intervention with IVMP is likely to increase the probability of achieving a better long-term outcome and reducing the total dose of corticosteroids in ocular MG. Trial completion date: Jan 2023 --> Sep 2023 | Trial primary completion date: Dec 2022 --> Jul 2023
  • ||||||||||  Clinical heterogeneity in epidermolysis bullosa simplex with plectin (PLEC) mutations (Level 3 - Room 331) -  Apr 24, 2023 - Abstract #WCD2023WCD_2364;    
    We thus append the mutation database of plectin mutations in EBS and the clinical insights involved in these cases are beneficial in deciphering the facets of EB with plectin deficiency.Our observations propose to append a phenotype of EBS, hoarseness of voice and nail dystrophy or LOC-like phenotype with plectin mutations. Long-term follow up is necessary to monitor for the development of muscular dystrophy
  • ||||||||||  Review, Journal:  Serological diagnosis of myasthenia gravis and its clinical significance. (Pubmed Central) -  Apr 24, 2023   
    Herein, we review the different methods for detection of various antibodies involved in MG and their sensitivity and specificity. The understanding of these elements should be useful for improving the diagnosis and determining how to adapt the existing therapies to the requirements of each patient.